---

The Rise of China’s Biotech Industry and the Challenges for Taiwan

I. The Rapid Rise of China’s Biotech Industry

Over the past decade, China’s biotech industry has begun to make its mark on the global stage. This phenomenon is not accidental but the result of multiple structural factors. First, with China’s rapid economic growth, an active capital market, and abundant funding, biotech companies have gained access to significant resources. Many startups are able to secure large investments in a short time, accelerating clinical trials and international collaborations.

Second, improvements in research capacity and technological sophistication have allowed China to gradually shed its former image of “learning and imitation” and move toward independent innovation. In recent years, many innovative drugs have been launched first in China and have even received recognition from international regulatory bodies. Emerging fields such as immunotherapy, gene editing, and cell therapy have become key breakthroughs for Chinese biotech firms.

II. Policy Reform and Market Dividends

In addition to capital and technology, policy reforms have played a critical role. The National Medical Products Administration (NMPA) has introduced regulatory liberalization, significantly improving approval efficiency while aligning more closely with international standards. Approval processes that once took years have now been shortened considerably, allowing innovative drugs to reach the market faster.

Meanwhile, healthcare insurance reforms have included many high-priced innovative drugs in reimbursement lists, reducing patient burdens and expanding market demand. Coupled with China’s massive population base and a rapidly growing middle class, demand for high-quality healthcare and innovative medicines continues to rise, serving as a powerful engine for industry growth.

III. Talent Return and Enhanced Global Competitiveness

The United States’ push toward de-globalization, particularly through restrictions in technology and biomedical fields, has indirectly encouraged many Chinese scientists and professionals to return home. These internationally trained experts, many with multinational corporate experience, have infused China’s biotech sector with fresh vitality. Supported by local capital and favorable policies, they have quickly become pivotal forces in drug development, clinical trial design, and cross-border cooperation.

As capital, technology, policy, and talent converge, China has gradually built a complete biotech ecosystem—from R&D and clinical trials to manufacturing and commercialization—placing it in a position to compete directly with Western pharmaceutical giants. This means China is no longer just a participant in the global supply chain but is increasingly becoming a new driver of global innovation.

IV. The Impact on Taiwan: Crowding-Out Effects

The rapid rise of China’s biotech industry also presents clear challenges for Taiwan. The first is the crowding-out effect on capital. International investors are more inclined to invest in China, given its massive market and proactive policies, reducing Taiwan’s attractiveness for fundraising.

The second challenge lies in competition for technology and talent. As China continues to absorb high-level researchers, Taiwan’s already limited talent pool faces greater risk of brain drain, weakening local R&D capacity. In addition, Taiwan’s relatively small market size means that without a strong internationalization strategy, it risks being marginalized.

V. Taiwan’s Response Strategies

Facing pressure from China, Taiwan must take bold and innovative actions:

1. Regulatory Reform:
   Taiwan should accelerate its drug approval process and align with international standards. For example, if a new drug has been approved in the top ten advanced countries, Taiwan should quickly follow suit to shorten patient waiting times and enhance market appeal.

2. Active Internationalization:
   Taiwanese biotech firms must aggressively expand overseas, especially in the U.S., where funding and market opportunities are abundant. Through international collaborations, U.S. listings, or partnerships with multinational companies, they can boost visibility and secure resources.

3. Resource Integration:
   Since most Taiwanese biotech firms are relatively small, they should pursue strategic alliances or form industrial clusters to share resources in clinical trials, regulatory affairs, and international marketing, thereby enhancing overall competitiveness.

4. Global Vision and Professional Managers:
   Industry leaders must cultivate global perspectives and leverage the expertise of foreign professional managers. Introducing multinational experience and operational models can accelerate Taiwan’s internationalization.

VI. The Long-Term Nature of the Biotech Industry

It is important to emphasize that biotech is different from the IT industry. Its life cycle is longer, its risks are higher, and it requires sustained investment and patience. Drug development typically takes more than a decade, requires billions of dollars, and faces extremely high failure rates. Therefore, managing biotech firms with only a short-term, capital market mindset often leads to disappointment.

For Taiwan to secure a place in the global biotech landscape, it must adopt a pragmatic approach, committing to medium- and long-term development. This requires building a solid clinical and R&D foundation and gradually accumulating credibility and international partnerships.

VII. Conclusion

The rise of China’s biotech industry is reshaping the global pharmaceutical innovation landscape. For Taiwan, this represents both competitive pressure and a driving force for reform. Only by accelerating regulatory liberalization, promoting internationalization, integrating resources, and cultivating global-minded leadership can Taiwan avoid marginalization and maintain influence in the medium- to long-term biotech competition.

The core of the biotech industry lies not in short-term financial returns but in sustained technological breakthroughs and international collaboration. If Taiwan can combine patience and confidence with supportive policies and pragmatic business development, it still has the potential to play an important role on the global stage.

---